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ABSTRACT
Objectives: The psychological effects of acute
pulmonary embolism (PE) have scarcely been studied.
The aims of this study were to evaluate health-related
quality of life (HRQoL) in patients with a history of PE
compared with that of the general population and
buddy controls, and to explore factors that may predict
impaired HRQoL.
Design: Cross-sectional.
Setting: Haematology and thrombosis unit in
Fredrikstad, Norway.
Participants: 213 consecutive patients treated for PE
were identified from hospital registries. Eligible patients
were scheduled for a single study visit, including a
functional capacity test (6 min walking test). HRQoL
was assessed using the EuroQol 5D dimensions 3-level
(EQ-5D-3L) questionnaire, of which the results were
compared with Danish population norms and age-
matched and sex-matched buddy controls. The buddy
controls were recruited by asking every patient to hand
over the EQ-5D questionnaire to 2 age-matched and
sex-matched friends or relatives. Multivariable
regression analyses were used to examine possible
determinants of reduced HRQoL.
Results: Mean age was 61 years (SD 15), 117 (55%)
were males, and median time since diagnosis was
3.8 years (range 0.3–9.5). Mean EuroQol visual
analogue scale (EQ VAS) was 67 in PE as compared
with 81 in the general population (p<0.005) and
corresponding EQ-5D index values were 0.80 and 0.86
(p<0.005). Patients reported more problems in all 5
EQ-5D compared with both the buddy controls and the
general population, p<0.05. Shorter 6 min walking
distance (β=0.09, p<0.005) and patient-reported
dyspnoea (β=11.27, p<0.005) were independent
predictors of lower EQ VAS scores.
Conclusions: Our findings show that patients with a
history of PE have impaired HRQoL when compared
with the general population and buddy controls.
Reduced functional capacity and persistent dyspnoea
were the main predictors of this impairment.
INTRODUCTION
Health-related quality of life (HRQoL) after
deep vein thrombosis (DVT) has been
extensively studied. The interest in studying
HRQoL in DVT is believed to be related to
the well-characterised frequent detrimental
chronic condition of post-thrombotic syn-
drome (PTS) that affects 30–50% of patients
with DVT.1 Unlike DVT, long-term effects of
acute pulmonary embolism (PE) on HRQoL
are understudied. The equivalent long-term
complication of acute PE is chronic thrombo-
embolic pulmonary hypertension (CTEPH).2
This condition has been shown to affect 2–
4% of the patients with a history of PE.3 This
relatively low frequency of CTEPH may be
the reason for the limited number of studies
focusing on HRQoL and the psychological
well-being of patients with PE.4–9 It has been
suggested that CTEPH itself is the extreme
manifestation of a much more common phe-
nomenon of permanent changes in pulmon-
ary haemodynamics, cardiac function and
pulmonary gas exchange after acute PE,
which is associated with dyspnoea and
decreased exercise capacity. Additionally,
several studies have shown that up to 50% of
the patients with a history of PE report per-
sistent dyspnoea a long time after PE.4 10 By
analogy with PTS after DVT, it was recently
Strengths and limitations of this study
▪ This study describes the long-term health-related
quality of life, functional capacity and prevalence
of dyspnoea in patients with a history of pulmon-
ary embolism, which have scarcely been studied.
▪ A large sample size in which all aspects of a
generic health-related quality of life questionnaire
is reported combined with functional capacity
assessment.
▪ The findings of this study may encourage future
studies to evaluate the susceptibility of these
patients to cardiopulmonary rehabilitation.
▪ The low response rate and the retrospective
design may hamper external validation.
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proposed to refer to this phenomenon as the ‘postpul-
monary embolism syndrome’.11 Moreover, a recent
Scandinavian study reported the overuse of antidepres-
sants in adolescents with a history of PE, indicating that
PE may develop into a chronic illness in a relevant
number of patients.12 Indeed, the few existing studies all
report an impaired HRQoL in patients with a history of
PE compared with that of the normal population,4 6
although the results concerning possible predictors of
reduced HRQoL are divergent.7 A more detailed knowl-
edge of the determinants of HRQoL is needed to allow
for identiﬁcation of treatment targets and implementa-
tion of this important end point in future outcome
studies.
The aims of this study were to compare HRQoL in
patients with a history of PE to that of the general popu-
lation and age-matched and sex-matched controls, and
to evaluate possible determinants of HRQoL.
MATERIALS AND METHODS
Participants and setting
Consecutive patients who were diagnosed and treated
for PE at the Østfold Hospital Trust, Fredrikstad,
Norway, between January 2002 and December 2011
were identiﬁed from the hospital’s registries including
the thrombosis registry by searching for International
Classiﬁcation of Diseases (ICD)-10 codes of PE
(ICD-10 I26.0 and I26.9). All patients alive at the
beginning of March 2012, and with a PE diagnosis
conﬁrmed by CT pulmonary angiogram or high prob-
ability perfusion scintigraphy, were eligible for study
participation.
Patients were excluded if they were aged <18 or
>90 years or deemed incapable of complying with study
procedures, including language barriers, geographical
unavailability, known dementia, psychiatric diagnosis
such as major depression as well as affective disorders or
any degree of psychotic disorder. Patients living in
nursing homes or receiving major help from social care
services were excluded as well.
Written informed consent was obtained for all
patients.
Study design
All eligible patients were contacted by telephone and
invited to participate in the study. Patients who
responded to our invitation were scheduled for a visit
during which they underwent physical examination and
functional capacity test using the 6 min walking test. The
6 min walking test is a standardised functional capacity
test, which is widely used to objectively assess patients’
cardiopulmonary capacity.13 The test was performed
according to published guidelines,14 by one of the study
investigators (MT). For each patient, we derived pre-
dicted values from the recommendations of the litera-
ture.15 Evaluation of patients comprised blood tests
including brain natriuretic peptide (BNP), which were
obtained at the study visit. Sociodemographic data were
recorded on standardised case record forms.
Prior to the study visit, the HRQoL questionnaire was
sent to the patients either by email or post. Patients were
asked to complete the form at home and return it at the
scheduled study visit. Incomplete forms were completed
during the visit at the hospital.
Quality of life questionnaire
The validated Norwegian version of the EuroQol ﬁve-
dimension three-level (EQ-5D-3L) questionnaire was
used in order to assess quality of life (QoL). EQ-5D-3L
consists of a descriptive system and the EuroQol visual
analogue scale (EQ VAS).16 17 The EQ-5D-3L is a vali-
dated, generic, preference-based, health status measure
consisting of ﬁve descriptive questions encompassing ﬁve
domains of HRQoL: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. Each question
is answered based on three response options (1=‘no
problems’, 2=‘moderate problems’, 3=‘severe pro-
blems’). The 243 (35) potential patterns of responses
each indicate a unique health state ranging from 11 111
for perfect health to 33 333 for the worst possible state.
The health states can then be converted into a single
summary index value, which ranges from 1 (state of full
health) to values lower than 0 (states regarded as worse
than being dead).
The EQ VAS is a self-rated health on a vertical visual
analogue scale (0–100) where the end points are
labelled ‘worst imaginable health state’ and ‘best imagin-
able health state’.
Control groups
Although several European countries have established
normative population data for the EQ-5D instrument,
these are not available for Norway. Therefore, we com-
pared our results to the Danish population norms that
were established in 2009.18
To correct for incident cases with venous thrombosis
in the normative population, we included a second
control group by asking our study participants to recruit
two age-matched (±5 years) and sex-matched relatives or
friends without a history of venous thrombosis, hereafter
referred to as buddy controls, to complete the EQ-5D
form. Buddy controls were asked to return the anonym-
ous questionnaire in prepaid envelopes. Owing to the
anonymity of the buddy controls, further baseline
characteristics were not accessible.
Predictors
On the basis of clinical experience and previous
research, we hypothesised that the following determi-
nants may be relevant predictors of HRQoL after PE:
(1) age, (2) sex, (3) disease duration (time in years
from PE diagnosis to study visit), (4) body mass index
(kg/m2), (5) recurrent venous thromboembolism, (6)
occupation, (7) persistent patient-reported dyspnoea,
(8) performance at 6 min walking test, (9) BNP, (10)
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active malignancy, (11) ongoing anticoagulant treat-
ment, (12) known cardiopulmonary comorbidity, includ-
ing interstitial pulmonary diseases, congestive heart
failure and chronic obstructive pulmonary disease and
(13) proximal clot location at PE diagnosis as assessed
by a previously published radiological score by Ghanima
et al.19
STATISTICAL ANALYSES
Continuous variables were expressed as means and SDs
if normally distributed and as medians with ranges if the
distribution was skewed. Categorical variables were pre-
sented as percentages and/or frequencies. Comparisons
were made using Student’s t-test or Mann-Whitney U test
(depending on normal or skewed distribution) for con-
tinuous variables and χ2 tests for categorical variables.
Since very few patients and controls had ‘extreme pro-
blems’, the EQ-5D were dichotomised to either ‘no pro-
blems’ or ‘problems’.
Age and gender adjustment of controls was made by
weighing the population norm EQ-5D index values and
EQ VAS with the distribution of our sample, as recom-
mended by Hjermstad et al.20
Variables deemed predictive of HRQoL were ﬁrst
screened using univariate analysis (Spearman’s r).
Correlations below the signiﬁcance level of α=0.1 were
retained for the multivariate regression analysis.
Potential multicollinearity was checked before inclusion
in the multivariate models. Then multivariate regression
analyses comprising both standard linear regression and
binary logistic regression models were performed. For
the former, the possible determinants were tested for
independency against EQ VAS and r2 was used to esti-
mate the percentage of effect explained by the model.
For the latter, retained determinants from the univariate
analysis were tested for independency against each of
the EQ-5D dimensions. The Hosmer and Lemeshow test
was used to estimate the goodness of ﬁt of the model.
The multiple imputation model was used in order to
deal with missing values in the EQ-5D questionnaires of
the buddy controls in whom we did not have the possi-
bility to check and complete the questionnaires during a
study visit.21 Cases with more than 50% of the items or
EQ VAS missing were omitted. All analyses were per-
formed using the Statistical Package for Social Science
V.22.0 (SPSS, Chicago, Illinois, USA), and considered
signiﬁcant at a two-sided α of ≤0.05.
RESULTS
Study flow
A total of 836 patients were identiﬁed and assessed for
eligibility in this study. As shown in the study ﬂow chart
(ﬁgure 1), 430 (51%) patients were excluded according
to the predeﬁned exclusion criteria. Of the 406 remain-
ing and thus invited patients, 189 (46%) declined to par-
ticipate. Of the remaining 217 eligible patients, 213
completed both the EQ-5D questionnaire and
underwent the 6 min walking test. Hence, the response
rate for our study cohort was 52%.
The number of buddy controls who returned the
EQ-5D form was 205, of whom 28 returned question-
naires had more than 50% of data missing. After exclud-
ing these 28, 177 were left for analysis. The response
rate for the buddy controls was thus 42%, assuming all
study patients indeed forwarded the questionnaire to
two ‘buddies’.
Study patients
Patients had a mean age of 61 years (SD 15) and 55%
were men (n=117). Sociodemographic characteristics
are presented in table 1. Median time since diagnosis
was 3.8 years (range 0.3–9.5) with 89% being diagnosed
with PE more than a year prior to study inclusion.
Mean distance covered on the 6 min walking test by
the study cohort was 449 m (SD 135). The mean 6 min
walking distance was 97 m (95% CI 76 to 117) less in
male patients and 84 m (95% CI 65 to 104) less in
female patients as compared with their gender-predicted
value, p<0.005.
Comparison of HRQoL between patients, population
controls and buddy controls
Table 2 shows the frequency of reported problems by
dimension as well as mean and median values for EQ
VAS and EQ-5D index values stratiﬁed by age group. The
dimensional difference between patients and both of the
control groups yielded statistically signiﬁcant differences
across all dimensions (ﬁgure 2). Comparisons of EQ-5D
index values and EQ VAS between patient and control
groups are presented in table 3. A comparison with the
male proportion of our sample to that of the Danish
population norms regarding EQ-5D index values initially
showed a statistically signiﬁcant difference, p=0.04
(0.84 vs 0.88). However, after adjusting for outliers, the
statistical signiﬁcance disappeared (0.85 vs 0.87, p=0.13).
Figure 1 Study flow chart. 6MWT, 6 min walking test;
EQ-5D-3L, EuroQol five-dimension three-level; HRQoL, health
related quality of life; PE, pulmonary embolism; QoL, quality
of life.
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The differences in mean EQ-5D index values were 0.11
and 0.06 between patients and buddy controls and
between patients and the general population,
respectively.
Predictors of HRQoL
Table 4 summarises the results of the univariate analysis.
The 6 min walking test was signiﬁcantly correlated with
all the EQ-5D dimensions as well as EQ VAS (p<0.005),
indicating that patients with lower scores on EQ VAS or
reporting problems in the EQ-5D tended to walk shorter
distances. Similar associations were found concerning
dyspnoea, as those reporting dyspnoea reported pro-
blems in four out of ﬁve EQ-5D dimensions (p<0.05;
table 4). Patients reporting dyspnoea also tended to
cover shorter distances on the 6 min walking test (481 vs
413 m, p<0.005). In the multiple linear regression
model, the following variables were shown to be
independently predictive of the dependent variable EQ
VAS: performance on 6 min walking test (β=0.09,
p<0.005), symptoms of dyspnoea (β=−11.27, p<0.005)
and unemployment (β=−8.98, p<0.005; table 5). In add-
ition to the EQ VAS, performance on the 6 min walking
test consistently proved to be an independent determin-
ant of every EQ-5D dimension, except for the dimension
anxiety and depression. Dyspnoea was a signiﬁcant pre-
dictor of the dimension usual activities and pain and dis-
comfort. However, regarding the latter, the goodness of
ﬁt of the model showed a value beneath the signiﬁcance
level of 0.05 (Hosmer and Lemeshow=0.02), indicating
the poor ﬁt of the model. None of the other evaluated
variables were signiﬁcant determinants of HRQoL. The
results from both the multiple linear and binary logistic
regression analyses are displayed in table 5.
DISCUSSION
In this population-based cross-sectional study, we found
that the long-term HRQoL assessed by EQ-5D-3L was sig-
niﬁcantly impaired among patients with PE compared
with buddy controls and population norms. Moreover,
we found that poorer performance on the 6 min
walking test, persistent patient-reported dyspnoea and
unemployment were independent predictors of reduced
HRQoL. To the best of our knowledge, this is the
second largest study to compare long-term HRQoL after
PE to a control group and the ﬁrst one to incorporate a
validated functional capacity test to a more comprehen-
sive evaluation of HRQoL in patients with PE. Despite
using a different instrument (EQ-5D-3L vs Short-Form
36 (SF-36)), our results of impaired HRQoL after PE
conﬁrm previously published studies.6 7
The challenge of QoL studies is to judge whether
identiﬁed differences are clinically relevant or not.
Across various HRQoL research papers using the EQ-5D
instrument, authors have suggested threshold values for
minimal (clinical) important difference (MID/MCID),
that is, the least amount of difference suggesting clinical
relevance or mandating a change in clinical practice,22
ranging from 0.04 to 0.08.23–25 In our study, the δ EQ-5D
index value between the study population and buddy
controls was 0.11 and between the study population and
the general population was 0.06. This indicates that we
have identiﬁed the clinically relevant difference in
HRQoL between the patients and both control cohorts.
Of note, the cut-off value for MID/MCID is various and
probably depends on the disease and valuation sets
used. Moreover, since we did not include a longitudinal
within-person measurement of QoL, the differences
must be interpreted with caution.26
Compared with those without dyspnoea, 46.5% of our
study patients who reported persistent dyspnoea per-
formed worse in the 6 min walking test, objectively veri-
fying this symptom. As for the whole study cohort, both
male and female patients walked signiﬁcantly shorter
distances than their gender predicted value. In the
Table 1 Sociodemographic and clinical characteristics of
the study sample
Variable Study sample
n (%)
Female 96 (45)
Age in years, mean (SD) 61 (15)
Years since diagnosis, median (range) 3.8 (0.3–9.5)
Occupation
Unemployed 50 (24)
Working 71 (33)
Retired 92 (43)
Diagnosis
PE 149 (70)
PE+DVT 64 (30)
Recurrent VTE 34 (16)
Cardiopulmonary comorbidity 19 (9)
BMI, mean (SD) 28.7 (4.9)
Obesity 73 (34)
Active malignancy 15 (7)
Reporting dyspnoea 99 (46)
Smoking
Current 38 (18)
Former 52 (24)
Ongoing AC treatment 81 (38)
6MWT, mean (SD)
Total 449 (135)
Men 488 (124)
Women 402 (134)
Laboratory tests at study visit 203
BNP, mean (SD) 48.6 (72.4)
F-score 192
Median (range) 3 (1–4)
6MWT, 6 min walking test measured in metres; BMI, body mass
index (kg/m2), obesity=BMI>30 kg/m2; BNP, brain natriuretic
peptide (mg/l); F-score, Fredrikstad radiological score (higher
scores associated with a more proximal location of the thrombus);
Ongoing AC treatment, ongoing anticoagulant treatment at
inclusion; PE, pulmonary embolism; PE+DVT, concomitant deep
vein thrombosis reported in hospital records at PE diagnosis;
Unemployed, unemployed or unemployment because of long-term
illness or disability retirement; Working, working or studying.
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multivariable analyses, performance on the 6 min
walking test and persistent dyspnoea appeared to be
independent predictors of worse HRQoL. This may indi-
cate that patients with PE suffer from a reduced func-
tional capacity that persists for many years after the
event and that the declining functional capacity is one
of the main determinants of impaired HRQoL in
patients with a history of PE. The ﬁnding that patients
on average underperformed in the 6 min walking test
may thus be an important explanation for their overall
reduced HRQoL. This ﬁnding could be further sup-
ported by a qualitative study in patients with PE reveal-
ing that modiﬁcation of physical activity and exertion
(avoidance or reduction) was the most common behav-
iour change reported by the interviewed patients.8
Again, however, cut-off values for the clinically relevant
abnormal 6 min walking test performance regarding PE
are lacking, which makes it difﬁcult to put the observed
results in further perspective. Furthermore, we cannot
exclude that this correlation also could be reversed,
Table 2 Frequency of patients (n=213) reporting problems in the EQ-5D dimensions, means and medians for EQ VAS and
EQ-5D index values. All displayed by age groups
Age groups
18–29 30–39 40–49 50–59 60–69 70–79 80+ Total
EQ-5D
Mobility, N (%) 2 (1) 4 (2) 6 (3) 8 (4) 12 (6) 13 (6) 10 (5) 55 (26)
Self-care, N (%) 0 (0) 0 (0) 2 (1) 3 (1) 3 (1) 5 (2) 1 (0.5) 14 (7)
Usual activities,
N (%)
2 (1) 4 (2) 9 (4) 10 (5) 20 (9) 11 (5) 12 (6) 68 (32)
Pain and
discomfort, N (%)
3 (1) 8 (4) 15 (7) 21 (10) 28 (13) 24 (11) 17 (8) 116 (54)
Anxiety and
depression, N (%)
3 (1) 4 (2) 9 (4) 8 (4) 23 (11) 13 (6) 10 (5) 70 (33)
EQ VAS
Mean (SD) 61 (22) 65 (23) 67 (23) 70 (22) 70 (21) 70 (18) 57 (21) 67 (21)
Median 60 73 70 75 70 70 51 70
25th 45 49 50 50 53 51 40 50
75th 80 84 85 87 90 82 75 83
EQ-5D index values
Mean (SD) 0.67 (0.40) 0.81 (0.26) 0.81 (0.23) 0.84 (0.21) 0.81 (0.16) 0.80 (0.25) 0.74 (0.18) 0.80 (0.22)
Median 0.27 0.73 0.76 0.77 0.71 0.73 0.71 0.72
25th 0.82 0.82 0.82 0.82 0.79 0.82 0.77 0.82
75th 1.00 1.00 1.00 1.00 1.00 1.00 0.82 1.00
EQ-5D,EuroQol five-dimension; EQ VAS, EuroQol visual analogue scale.
Figure 2 Proportion of patients,
Danish population and buddy
controls reporting problems
stratified by EQ-5D dimensions.
EQ-5D, EuroQol five-dimension.
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meaning that the reduced HRQoL is due to the low
physical performance.
Numerous studies have shown the beneﬁcial effects of
pulmonary rehabilitation in other cardiovascular dis-
eases, resulting in improved functional capacity as well
as HRQoL.27–30 In this context, our ﬁndings support the
hypothesis that patients with PE with persistent dyspnoea
and poor functional status may beneﬁt from cardiopul-
monary rehabilitation programmes.31
Although the majority of studies focusing on the long-
term effects of PE have not excluded patients with estab-
lished CTEPH diagnosis, there is consistent reporting
that approximately half of the patients assessed more
than 6 months after experiencing an episode of acute
PE report dyspnoea, which is also correlated to a decline
in physical performance measured by the 6 min walking
test.4 10 32 33 Our results conﬁrm these ﬁndings and
support the concept of ‘post-PE syndrome’, which has
recently been presented as an analogy to PTS, referring
to the persistent dyspnoea and reduced functional cap-
acity after PE.11 The authors discuss whether PE could
in some cases, CTEPH excluded, be classiﬁed as a
chronic illness and postulate the ‘post-PE syndrome’
being a state just prior to development of CTEPH. This
reasoning is further strengthened by a Danish study
reporting the overuse of antidepressants in adolescents
long after they experienced their ﬁrst episode of PE.12
However, whether persistent dyspnoea after PE should
be the subject of further standardised workup including
HRQoL questionnaires and the 6 min walking test is still
debatable since some studies attribute the high preva-
lence of dyspnoea to pre-existing comorbidities.34 The
ﬁnal independent predictor of worse HRQoL in our
study was unemployment. Several sociodemographic
variables have previously been shown to affect HRQoL,
regardless of the underlying disease or condition.35 The
fact that 24% of the study population were unemployed
could possibly have contributed to the overall lower
HRQoL scores in our patient cohort. Furthermore, we
hypothesise that the association between impaired
HRQoL and unemployment may be subject to reverse
correlation, that is, impaired HRQoL leading to
unemployment. However, owing to missing data on
other social factors, we could not investigate this further.
Of the predeﬁned determinants being evaluated, we
found only a selected proportion predictive of worse
HRQoL and, to our surprise, malignancy appeared not
to be a signiﬁcant determinant of HRQoL. Previous
studies have found cardiopulmonary disease, active
malignancy as well as obesity being independent predic-
tors of HRQoL.6 36 However, the proportions of these
subgroups reported in the aforementioned studies are
higher than in ours and the presented multivariate
regression analysis yielded rather low r2 percentages indi-
cating the models not being precise.6 This may indicate,
as van Es et al7 postulate, that in this study the patients
are somewhat healthier and subsequently, perhaps
emphasising the ﬁndings regarding the reported differ-
ences in HRQoL between study participants and the
general population. Nevertheless, in our view, these con-
tradictions exemplify the heterogeneous effects of PE as
a disease on HRQoL and physical capacity and conse-
quently rendering cumbersome the evaluation of deter-
minants of HRQoL in patients with PE.
Limitations
Our study has some limitations. The low response rate
may hamper the external validity of our results.
Moreover, since the ﬁnal study cohort comprised one-
quarter of the patients being assessed for eligibility, a
possible bias towards recruitment of patients with more
persistent symptoms cannot be ruled out. However, the
6 min walking test results and proportion reporting dys-
pnoea in our sample are similar to those of prior PE
follow-up studies,10 33 37 highlighting that our cohort is
a representative PE population. Also, the buddy control
group could not be assessed for potential confounders
because we did not assess their characteristics.
Therefore, we cannot rule out a bias towards ‘extremely’
healthy buddies or poor matching. Furthermore, owing
to the study’s retrospective design, which carried
missing data concerning the index event of the PE, we
could not classify the PE episode as being of low or
intermediate risk.
Table 3 Comparisons of mean EQ-5D index values and EQ VAS between patients versus Danish population and patients
versus buddy controls
Patients Danish population* Buddy controls
Male Female Total Male Female Total Total
EQ-5D index
Mean (SD) 0.85 (0.21) 0.75 (0.23) 0.80 (0.22) 0.87 0.84 0.86 0.91 (0.16)
p Value 0.13† <0.005† <0.005† <0.005‡
EQ VAS
Mean (SD) 71 (20) 62 (22) 67 (21) 81 80 81 80 (19)
p Value <0.005† <0.005† <0.005† <0.005‡
*Age-adjusted and sex-adjusted values.
†One sample t-test with the age-adjusted and sex-adjusted value as test value (two-sided).
‡Mann-Whitney U test (two-sided).
EQ-5D, EuroQol five-dimension; EQ VAS, EuroQol visual analogue scale.
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Table 4 Univariate analysis displaying correlations of the predefined determinants to EQ-5D dimensions and EQ VAS
EQ-5D EQ VAS
MO SC UA PD AD
N Corr.coef p Value Corr.coef p Value Corr.coef p Value Corr.coef p Value Corr.coef p Value Corr.coef p Value
Age 213 0.09 0.19 0.05 0.49 0.07 0.32 0.06 0.39 0.06 0.38 −0.06 0.31
Sex 213 −0.20* <0.05 −0.03 0.70 −0.23* <0.05 −0.13* 0.06 −0.27* <0.05 0.23* <0.05
6MWT 213 −0.43* <0.05 −0.28* <0.05 −0.42* <0.05 −0.30* <0.05 −0.25* <0.05 0.51* <0.05
BMI 213 0.13* 0.06 0.14* 0.04 0.10 0.16 0.03 0.71 0.05 0.50 0.22* <0.05
BNP 203 0.19* 0.01 0.01 0.89 0.15* 0.03 0.13* 0.07 0.19* 0.01 −0.10 0.14
Ongoing AC 213 0.09 0.19 −0.05 0.45 0.02 0.73 0.02 0.80 −0.01 0.85 −0.06 0.38
Cardiopulmonary comorbidity 213 0.15* 0.03 0.05 0.47 0.17* 0.01 0.09 0.20 0.06 0.20 −0.19* 0.01
Active cancer 213 0.09 0.20 0.01 0.99 0.01 0.90 −0.01 0.93 0.01 0.97 −0.02 0.77
Reporting dyspnoea 213 0.16* 0.02 0.13* 0.05 0.29* <0.05 0.40* <0.05 0.11 0.11 −0.37* <0.05
F-score 192 0.06 0.42 0.15* 0.04 0.11 0.13 0.07 0.36 −0.01 0.94 −0.12* 0.09
Recurrent VTE 213 0.01 0.93 −0.06 0.35 −0.02 0.73 0.06 0.35 −0.01 0.95 −0.02 0.77
Unemployed 213 0.10 0.13 0.08 0.27 0.22* <0.05 0.24* <0.05 0.27* <0.05 −0.24* 0.01
Disease duration 213 −0.02 0.77 −0.02 0.79 −0.03 0.64 −0.04 0.58 −0.07 0.32 0.13* 0.05
*All values with α<0.10 retained for multiple regression analysis, explanatory variables recoded to 0=not having the condition and 1=having the condition, dimensions dichotomised in reporting
problems=1 and not reporting problems=0.
6MWT, 6 min walking test; AD, anxiety and depression; Age, age at inclusion, male sex=1; BMI, body mass index (kg/m2); BNP, brain natriuretic peptide; Corr. coef, Spearman’s r correlation
coefficient; EQ-5D, EuroQol five-dimension; EQ VAS, EuroQol visual analogue scale; F-score, Fredrikstad radiological score (higher scores associated with a more proximal location of the
thrombus); MO, mobility; Ongoing AC, ongoing anticoagulant treatment; PD, pain and discomfort; SC, self-care; UA, usual activities; Unemployed, unemployed or unemployment because of
long-term illness or disability retirement and disease duration=time in years from PE diagnosis to study inclusion.
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Table 5 Multiple binary logistic and standard linear regression models with retained determinants from the univariate analysis for possible independency tested against
EQ-5D dimensions and EQ VAS
EQ-5D EQ VAS
MO SC UA PD AD
OR 95% CI OR 95% Cl OR 95% CI OR 95% CI OR 95% CI β† SE‡
6MWT 0.991 0.987 to 0.995** 0.990 0.984 to 0.997** 0.991 0.988 to 0.995** 0.996 0.992 to 0.999* 0.997 0.994 to 1.000 0.09 0.01**
BMI 1.04 0.97 to 1.12 1.06 0.94 to 1.19 – – – – – – −0.07 0.26
BNP 1.00 1.00 to 1.01 – – 1.00 1.00 to 1.01 1.00 0.99 to 1.00 1.00 1.00 to 1.01 – –
Cardiopulmonary comorbidity 0.57 0.14 to 2.30 – – 0.78 0.20 to 3.07 – – – – 1.63 4.69
Reporting dyspnoea 1.33 0.63 to 2.81 1.74 0.38 to 8.07 2.33 1.14 to 4.78* 3.74 1.97 to 7.08** – – −11.27 2.56**
F-score – – 3.12 0.79 to 5.69 – – – – – – 1.71 1.13
Unemployed – – – – 2.55 1.15 to 5.67* 2.76 1.24 to 6.15* 3.94 1.88 to 8.26** −8.98 2.97**
Disease duration – – – – – – – – – – −0.19 0.47
Hosmer and Lemeshow 0.08 0.87 0.35 0.02 0.62
r2 0.46
*p Value <0.05 all regression models adjusted for age and sex, explanatory variables recoded to 0=not having the condition and 1=having the condition, dimensions dichotomised in reporting
problems=1 and not reporting problems=0.
**p Value <0.005, all regression models adjusted for age and sex, explanatory variables recoded to 0=not having the condition and 1=having the condition, dimensions dichotomised in reporting
problems=1 and not reporting problems=0.
†Unstandardised β coefficient.
‡SE of β.
6MWT, 6 min walking test; AD, anxiety and depression, higher scores in EQ VAS associated with better health related quality of life; BMI, body mass index (kg/m2); BNP, brain natriuretic
peptide; EQ-5D, EuroQol five-dimension; EQ VAS, EuroQol visual analogue scale; F-score, Fredrikstad radiological score (higher scores associated with a more proximal location of the
thrombus); MO, mobility; PD, pain and discomfort; SC, self-care; UA, usual activities; Unemployed, unemployed or unemployment because of long-term illness or disability retirement, disease
duration=time in years from diagnosis to study inclusion.
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The EQ-5D was used based on its simplicity and poten-
tial positive inﬂuence on patients’ completeness of
scores. It could be argued, however, that the SF-36 might
have been a good choice as well, due to its comprehen-
siveness and in order to compare our results with previ-
ous studies. Finally, we did not apply a disease-speciﬁc
questionnaire of QoL.
The strong points of this study are the sample size and
the long-term follow-up period with 89% of the patients
being diagnosed with PE more than 1 year prior to
inclusion. Furthermore, this study is one of the largest
studies to present a more comprehensive evaluation of
HRQoL by reporting all aspects of a generic QoL ques-
tionnaire as well as incorporating a functional capacity
test (6 min walking test) in order to objectify the
ﬁndings.
CONCLUSIONS
Patients with a history of acute PE were found to have a
worse HRQoL compared with age-matched and sex-
matched venous thromboembolism-free buddy controls
and population controls. Underperformance and
patient-reported dyspnoea were independent predictors
of decreased HRQoL. Further studies are necessary to
further evaluate the course and determinants of HRQoL
after acute PE, as well as interventions aimed at improv-
ing HRQoL in these patients.
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